PRODUCT MONOGRAPH

[Pr]LISINOPRIL/HCTZ (TYPE P)

(lisinopril as lisinopril dihydrate and hydrochlorothiazide)

10/12.5 mg, 20/12.5 mg and 20/25 mg Tablets

Angiotensin Converting Enzyme Inhibitor/Diuretic

Sanis Health Inc.
333 Champlain Street, Suite 102
Dieppe, New Brunswick
Canada, E1A 1P2

Date of Preparation:
February 8, 2011

Submission Control No: 144791

PRODUCT MONOGRAPH

[Pr]LISINOPRIL/HCTZ (TYPE P)

(lisinopril as lisinopril dihydrate and hydrochlorothiazide)

10/12.5 mg, 20/12.5 mg and 20/25 mg Tablets

Angiotensin-Converting Enzyme Inhibitor/Diuretic

ACTION AND CLINICAL PHARMACOLOGY

LISINOPRIL/HCTZ (TYPE P) (lisinopril and hydrochlorothiazide tablets) combines the action of an angiotensin-converting enzyme (ACE) inhibitor, lisinopril, and a diuretic, hydrochlorothiazide.

Lisinopril
Angiotensin-converting enzyme (ACE) is a peptidyl dipeptidase which catalyzes the conversion of angiotensin I to the pressor substance, angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II, which leads to increased plasma renin activity (due to removal of negative feedback of renin release) and decreased aldosterone secretion. Although the latter decrease is small, it results in a small increase in serum potassium. In patients treated with lisinopril plus a thiazide diuretic, there was essentially no change in serum potassium (see PRECAUTIONS).

ACE is identical to kininase II. Thus, lisinopril may also block the degradation of bradykinin, a potent vasodilator peptide. However, the role that this plays in the therapeutic effects of lisinopril is unknown.

While the mechanism through which lisinopril lowers blood pressure is believed to be primarily the suppression of the renin-angiotensin-aldosterone system, lisinopril also lowers blood pressure in patients with low-renin hypertension.

Pharmacodynamics

Lisinopril

Administration of lisinopril to patients with hypertension results in a reduction of both supine and standing blood pressure. Abrupt withdrawal of lisinopril has not been associated with a rapid increase in blood pressure. In most patients studied, after oral administration of an individual dose of lisinopril, the onset of antihypertensive activity is seen at one hour with peak reduction of blood pressure achieved by 6 hours. Although an antihypertensive effect was observed 24 hours after dosing with recommended single daily doses, the effect was more consistent and the mean effect was considerably larger in some studies with doses of 20 mg or more than with lower doses. However, at all doses studied, the mean antihypertensive effect was substantially smaller 24 hours after dosing than it was six hours after dosing. On occasion, achievement of optimal blood pressure reduction may require 2 to 4 weeks of therapy.

In hemodynamic studies in patients with essential hypertension, blood pressure reduction was accompanied by a reduction in peripheral arterial resistance with little or no change in cardiac output and in heart rate. In a study in nine hypertensive patients, following administration of lisinopril, there was an increase in mean renal blood flow that was not significant. Data from several small studies are inconsistent with respect to the effect of lisinopril on glomerular filtration rate in hypertensive patients with normal renal function, but suggest that changes, if any, are not large.

When lisinopril is given together with thiazide-type diuretics, its blood pressure lowering effect is approximately additive.

The antihypertensive effect of angiotensin-converting enzyme inhibitors is generally lower in black than in non-black patients.

Hydrochlorothiazide

Hydrochlorothiazide is a diuretic and antihypertensive which interferes with the renal tubular mechanism of electrolyte reabsorption. It increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate. While this compound is predominantly a saluretic agent, *in vitro* studies have shown that it has a carbonic anhydrase inhibitory action which seems to be relatively specific for the renal tubular mechanism. It does not appear to be concentrated in erythrocytes or the brain in sufficient amounts to influence the activity of carbonic anhydrase in those tissues.

Hydrochlorothiazide is useful in the treatment of hypertension. It may be used alone or as an adjunct to other antihypertensive drugs. Hydrochlorothiazide does not affect normal blood pressure. The mechanism of its antihypertensive action is not known. Lowering of the sodium content of arteriolar smooth muscle cells and diminished response to norepinephrine have been postulated.

Onset of the diuretic action following oral administration occurs in 2 hours and the peak action in about 4 hours. Diuretic activity lasts about 6 to 12 hours.

Pharmacokinetics

Lisinopril
Following oral administration of lisinopril, peak serum concentrations occur within about 7 hours. Declining serum concentrations exhibit a prolonged terminal phase which does not contribute to drug accumulation. This terminal phase probably represents saturable binding to ACE and is not proportional to dose. Lisinopril does not bind to plasma proteins other than ACE.

Lisinopril does not undergo metabolism and is excreted unchanged entirely in the urine. Based on urinary recovery, the extent of absorption of lisinopril is approximately 25%, with large inter-subject variability (6 - 60%) at all doses tested (5 - 80 mg).

Lisinopril absorption is not influenced by the presence of food in the gastrointestinal tract.

Upon multiple dosing, lisinopril exhibits an effective half-life of accumulation of 12 hours.

In a study in elderly healthy subjects (65 years and above), a single dose of lisinopril 20 mg produced higher serum concentrations than those seen in young healthy adults given a similar dose. In another study, single daily doses of lisinopril 5 mg were given for 7 consecutive days to young and elderly healthy volunteers. Maximum serum concentrations of lisinopril on Day 7 were higher in the elderly volunteers than in the young.

The elimination of lisinopril in patients with renal insufficiency is similar to that in patients with normal renal function until the glomerular filtration rate is 30 mL/min or less. With renal function ≤30 mL/min, peak and trough lisinopril levels increase, time to peak concentration increases and time to steady state may be prolonged (see DOSAGE AND ADMINISTRATION).

Studies in rats indicate that lisinopril crosses the blood-brain barrier poorly.

Hydrochlorothiazide
Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. The plasma half-life is 5.6 - 14.8 hours when the plasma levels can be followed for at least 24 hours. At least 61% of the oral dose is eliminated unchanged within 24 hours. Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.

Lisinopril - Hydrochlorothiazide
Concomitant administration of lisinopril and hydrochlorothiazide has little, or no effect on the bioavailability of either drug. The combination tablet is bioequivalent to concomitant administration of the separate entities.

INDICATIONS AND CLINICAL USE

LISINOPRIL/HCTZ (TYPE P) is indicated for the treatment of essential hypertension in patients for whom combination therapy is appropriate.

In using LISINOPRIL/HCTZ (TYPE P), consideration should be given to the risk of angioedema (see WARNINGS).

Lisinopril should normally be used in those patients in whom treatment with diuretic or beta-blocker was found ineffective or has been associated with unacceptable adverse effects.

LISINOPRIL/HCTZ (TYPE P) is not indicated for initial therapy. Patients in whom lisinopril and diuretic are initiated simultaneously can develop symptomatic hypotension (see PRECAUTIONS, Drug Interactions).

Patients should be titrated on the individual drugs. If the fixed combination represents the dosage determined by this titration, the use of LISINOPRIL/HCTZ (TYPE P) may be more convenient in the management of patients. If during maintenance therapy dosage adjustment is necessary, it is advisable to use individual drugs.

CONTRAINDICATIONS

LISINOPRIL/HCTZ (TYPE P) is contraindicated in patients who:

- are hypersensitive to any component of this product;
- have a history of angioneurotic edema relating to previous treatment with an angiotensin-converting enzyme inhibitor; and
- have hereditary or idiopathic angioedema.

Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.

WARNINGS

Serious Warnings and Precautions

When used in pregnancy, ACE inhibitors can cause injury or even death of the developing fetus. When pregnancy is detected, LISINOPRIL/HCTZ (TYPE P) should be discontinued as soon as possible (see WARNINGS - Use in Pregnancy, and INFORMATION FOR PATIENTS).

Angioedema

Angioedema has been reported in patients treated with lisinopril and hydrochlorothiazide. This may occur at any time during treatment. Angioedema associated with laryngeal edema and/or shock may be fatal. If angioedema occurs, LISINOPRIL/HCTZ (TYPE P) should be promptly discontinued and appropriate monitoring should be instituted to ensure complete resolution of symptoms prior to dismissing the patient. Where swelling is confined to the face, lips and mouth the condition will usually resolve without further treatment, although antihistamines may be useful in relieving symptoms. These patients should be followed carefully until the swelling has

resolved. However, where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, emergency therapy should be administered promptly when indicated. This includes giving subcutaneous adrenaline (0.5 mL 1:1000), and/or maintaining a patent airway. The patient should be under close medical supervision until complete and sustained symptom resolution has occurred.

The incidence of angioedema during ACE inhibitor therapy has been reported to be higher in black than in non-black patients.

Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see CONTRAINDICATIONS).

Hypotension
Symptomatic hypotension has occurred after administration of lisinopril, usually after the first or second dose or when the dose was increased. It is more likely to occur in patients who are volume depleted by diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. Therefore, LISINOPRIL/HCTZ (TYPE P) should not be used to start therapy or when a dose change is needed. In patients with severe congestive heart failure, with or without associated renal insufficiency, excessive hypotension has been observed and may be associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death. Because blood pressure could potentially fall, patients at risk for hypotension should start therapy with lisinopril under very close medical supervision, usually in a hospital. Such patients should be followed closely for the first two weeks of treatment and whenever the dose of lisinopril and/or hydrochlorothiazide is increased. In patients with ischemic heart or cerebrovascular disease, an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident (see ADVERSE REACTIONS).

If hypotension occurs, the patient should be placed in supine position and, if necessary, receive an intravenous infusion of normal saline. A transient hypotensive response may not be a contraindication to further doses. These can usually be given to hypertensive patients without difficulty once the blood pressure has increased after volume expansion. However, lower doses of lisinopril and/or concomitant diuretic therapy should be considered.

Neutropenia/Agranulocytosis
Agranulocytosis and bone marrow depression have been caused by angiotensin-converting enzyme inhibitors. Several cases of agranulocytosis and neutropenia have been reported in which a causal relationship to lisinopril cannot be excluded. Current experience with the drug shows the incidence to be rare. Periodic monitoring of white blood cell counts should be considered, especially in patients with collagen vascular disease and renal disease.

Azotemia
Azotemia may be precipitated or increased by hydrochlorothiazide. Cumulative effects of the drug may develop in patients with impaired renal function. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease the diuretic should be discontinued.

Patients with Impaired Liver Function
Hepatitis, jaundice (hepatocellular and/or cholestatic), elevations of liver enzymes and/or serum bilirubin have occurred during therapy with lisinopril in patients with or without pre-existing liver abnormalities (see ADVERSE REACTIONS). In most cases the changes were reversed on discontinuation of the drug.

Should the patient receiving LISINOPRIL/HCTZ (TYPE P) experience any unexplained symptoms (see Information for Patients), particularly during the first weeks or months of treatment, it is recommended that a full set of liver function tests and any other necessary investigation be carried out. Discontinuation of LISINOPRIL/HCTZ (TYPE P) should be considered when appropriate.

There are no adequate studies in patients with cirrhosis and/or liver dysfunction. LISINOPRIL/HCTZ (TYPE P) should be used with particular caution in patients with pre-existing liver abnormalities. In such patients baseline liver function tests should be obtained before administration of the drug and close monitoring of response and metabolic effects should apply.

Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.

Hypersensitivity Reactions
Sensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma.

The possibility of exacerbation or activation of systemic lupus erythematosus has been reported in patients treated with hydrochlorothiazide.

Use in Pregnancy
ACE inhibitors can cause fetal and neonatal morbidity and mortality when administered to pregnant women. Several dozen cases have been reported in the world literature. When pregnancy is detected, LISINOPRIL/HCTZ (TYPE P) should be discontinued as soon as possible.

The use of ACE inhibitor during the second and third trimester of pregnancy has been associated with fetal and neonatal injury including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios has also been reported, presumably resulting from decreased fetal renal function, associated with fetal limb contractures, craniofacial deformation, and hypoplastic lung development.

Prematurity and patent ductus arteriosus and other structural cardiac malformations, as well as neurologic malformations, have also been reported following exposure in the first trimester of pregnancy.

Infants with a history of *in utero* exposure to ACE inhibitors should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as a means of reversing hypotension and/or substituting for impaired renal function, however, limited experience with those procedures has not been associated with significant clinical benefits.

Lisinopril has been removed from the neonatal circulation by peritoneal dialysis.

Human Data
It is not known whether exposure limited to the first trimester of pregnancy can adversely affect fetal outcome. The use of ACE inhibitors during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios has also been reported, presumably resulting from decreased fetal renal function; oligohydramnios in this setting has been associated with fetal limb contractures, craniofacial deformation, and hypoplastic lung development. Prematurity and patent ductus arteriosus have also been reported, although it is not clear whether these occurrences were due to the ACE inhibitor exposure.

Animal Data
Lisinopril was not teratogenic in mice treated on days 6 - 15 of gestation with up to 1000 mg/kg/day (625 times the maximum recommended human dose). There was an increase in fetal resorptions at doses down to 100 mg/kg; at doses of 1000 mg/kg this was prevented by saline supplementation. There was no fetotoxicity or teratogenicity in rats treated with up to 300 mg/kg/day (188 times the maximum recommended dose) of lisinopril at days 6 - 17 of gestation. In rats receiving lisinopril from day 15 of gestation through day 21 postpartum, there was an increased incidence in pup deaths on days 2 - 7 postpartum and a lower average body weight of pups on day 21 postpartum. The increase in pup deaths and decrease in pup weight did not occur with maternal saline supplementation.

Lisinopril, at doses up to 1 mg/kg/day, was not teratogenic when given throughout the organogenic period in saline supplemented rabbits. Saline supplementation (physiologic saline in place of tap water) was used to eliminate maternotoxic effects and enable evaluation of the teratogenic potential at the highest possible dosage level. The rabbit has been shown to be extremely sensitive to angiotensin-converting enzyme inhibitors (captopril and enalapril) with maternal and fetotoxic effects apparent at or below the recommended therapeutic dosage levels in man.

Fetotoxicity was demonstrated in rabbits by an increased incidence of fetal resorptions at an oral dose of lisinopril of 1 mg/kg/day and by an increased incidence of incomplete ossification at the lowest dose tested (0.1 mg/kg/day). A single intravenous dose of 15 mg/kg of lisinopril administered to pregnant rabbits on gestation days 16, 21 or 26 resulted in 88% to 100% fetal death.

By whole body autoradiography, radioactivity was found in the placenta following administration of labelled lisinopril to pregnant rats, but none was found in the fetuses.

Use in Nursing Mothers
The presence of concentrations of ACE inhibitor have been reported in human milk. Use of ACE inhibitors is not recommended during breast-feeding.

PRECAUTIONS

Renal Impairment
As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function have been seen in susceptible individuals. In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, such as patients with bilateral renal artery stenosis, unilateral renal artery stenosis to a solitary kidney, or severe congestive heart failure, treatment with agents that inhibit this system has been associated with oliguria, progressive azotemia, and rarely, acute renal failure and/or death. In susceptible patients, concomitant diuretic use may further increase risk.

Use of LISINOPRIL/HCTZ (TYPE P) should include appropriate assessment of renal function.

Thiazides may not be appropriate diuretics for use in patients with renal impairment and are ineffective at creatinine clearance values of 30 mL/min or below (i.e., moderate or severe renal insufficiency).

Hyperkalemia
In clinical trials hyperkalemia (serum potassium >5.7 mEq/L) occurred in approximately 1.4% of hypertensive patients. In most cases these were isolated values which resolved despite continued therapy. Hyperkalemia was not a cause of discontinuation of therapy. Risk factors for the development of hyperkalemia may include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes (see Drug Interactions).

Valvular Stenosis, Hypertrophic Cardiomyopathy
There is concern on theoretical grounds that patients with aortic stenosis or hypertrophic cardiomyopathy might be at particular risk of decreased coronary perfusion when treated with vasodilators.

LISINOPRIL/HCTZ (TYPE P) should be given with caution to these patients.

Metabolism
Hyperuricemia may occur or acute gout may be precipitated in certain patients receiving thiazide therapy.

Thiazides may decrease serum PBI levels without signs of thyroid disturbance.

Thiazides have been shown to increase excretion of magnesium; this may result in hypomagnesemia.

Thiazides may decrease urinary calcium excretion. Thiazides may cause intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Marked hypercalcemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.

Increases in cholesterol, triglyceride and glucose levels may be associated with thiazide diuretic therapy.

Surgery/Anesthesia
In patients undergoing major surgery or during anesthesia with agents that produce hypotension, lisinopril blocks angiotensin II formation, secondary to compensatory renin release. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.

Thiazides may increase the responsiveness to tubocurarine.

Cough
A dry, persistent cough, which usually disappears only after withdrawal or lowering of the dose of LISINOPRIL/HCTZ (TYPE P) has been reported.

Such a possibility should be considered as part of the differential diagnosis of the cough.

Use in the Elderly
In general, blood pressure response and adverse experiences were similar in younger and older patients given similar doses of lisinopril. Pharmacokinetic studies, however, indicate that maximum blood levels and area under the plasma concentration time curve (AUC) are doubled in older patients so that dosage adjustments should be made with particular caution.

Pediatric Use
LISINOPRIL/HCTZ (TYPE P) has not been studied in children and, therefore, use in this age group is not recommended.

Anaphylactoid Reactions during Membrane Exposure
Anaphylactoid reactions have been reported in patients dialysed with high-flux membranes (e.g., polyacrylonitrile [PAN]) and treated concomitantly with an ACE inhibitor. Dialysis should be stopped immediately if symptoms such as nausea, abdominal cramps, burning, angioedema, shortness of breath and severe hypotension occur. Symptoms are not relieved by antihistamines. In these patients consideration should be given to using a different type of dialysis membrane or a different class of antihypertensive agent.

Anaphylactoid Reactions during LDL Apheresis
Rarely, patients receiving ACE inhibitors during low density lipoprotein (LDL)-apheresis with dextran sulfate have experienced life-threatening anaphylactoid reactions. These reactions were avoided by temporarily withholding ACE inhibitor therapy prior to each apheresis.

Anaphylactoid Reactions during Hymenoptera Desensitization
There have been isolated reports of patients experiencing sustained life-threatening anaphylactoid reactions while receiving ACE inhibitors during desensitizing treatment with hymenoptera (bees, wasp) venom. In the same patients, these reactions have been avoided when ACE inhibitors were temporarily withheld for at least 24 hours, but they have reappeared upon inadvertent rechallenge.

DRUG INTERACTIONS

Hypotension - Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril (see WARNINGS, and DOSAGE AND ADMINISTRATION).

Agents Increasing Serum Potassium: Since lisinopril decreases aldosterone production, elevation of serum potassium may occur. Potassium sparing diuretics such as spironolactone, triamterene or amiloride, or potassium supplements should be given only for documented hypokalemia and with caution and frequent monitoring of serum potassium since they may lead to a significant increase in serum potassium. Salt substitutes which contain potassium should also be used with caution.

Agents Causing Renin Release: The antihypertensive effect of LISINOPRIL/HCTZ (TYPE P) is augmented by antihypertensive agents that cause renin release (e.g. diuretics).

Agents Affecting Sympathetic Activity: Agents affecting sympathetic activity (e.g., ganglionic blocking agents or adrenergic neuron blocking agents) may be used with caution. Beta-adrenergic blocking drugs add some further antihypertensive effect to lisinopril.

Lithium: Lithium generally should not be given with diuretics or ACE inhibitors. Diuretic agents and ACE inhibitors reduce the renal clearance of lithium and add a high risk of lithium toxicity.

d-tubocurarine: Thiazide drugs may increase the responsiveness to tubocurarine.

Insulin: Insulin requirements in diabetic patients treated with thiazide diuretics may be increased. Diabetes mellitus which has been latent may become manifest during thiazide administration.

Alcohol, barbiturates, or narcotics: In the presence of thiazide diuretics, potentiation of orthostatic hypotension may occur.

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia may occur when given concomitantly with thiazide diuretics.

Pressor amines (e.g., norepinephrine): In the presence of thiazide diuretics, possible decreased response to pressor amines but not sufficient to preclude their use.

Non-Steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.

The antihypertensive effect of lisinopril may be diminished with concomitant non-steroidal anti-inflammatory drug use. In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs, the co-administration of ACE inhibitors may result in further deterioration of renal function.

Therefore, when LISINOPRIL/HCTZ (TYPE P) and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired antihypertensive effect is obtained.

INFORMATION FOR PATIENTS

Angioedema: Angioedema, including laryngeal edema, may occur during treatment with LISINOPRIL/HCTZ (TYPE P). Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips, tongue, difficulty in breathing) and to take no more drug until they have consulted with the prescribing physician.

Hypotension: Patients should be cautioned to report lightheadedness especially during the first few days of therapy. If actual syncope occurs, the patients should be told to discontinue the drug until they have consulted with the prescribing physician.

All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with their physician.

Neutropenia: Patients should be told to report promptly any indication of infection (e.g., sore throat, fever) which may be a sign of neutropenia.

Impaired Liver Function: Patients should be advised to return to the physician if he/she experiences any symptoms possibly related to liver dysfunction. This would include "viral-like symptoms" in the first weeks to months of therapy (such as fever, malaise, muscle pain, rash or adenopathy which are possible indicators of hypersensitivity reactions), or if abdominal pain, nausea or vomiting, loss of appetite, jaundice, itching or any other unexplained symptoms occur during therapy.

Hyperkalemia: Patients should be told not to use salt substitutes containing potassium without consulting their physician.

Pregnancy: Patients should be advised to stop taking the medication and to report promptly to their physician if they become pregnant, since the use of LISINOPRIL/HCTZ (TYPE P) during pregnancy can cause injury and even death of the developing fetus.

Nursing Mothers: Patients should be advised not to breast-feed while taking LISINOPRIL/HCTZ (TYPE P), as it is possible that LISINOPRIL/HCTZ (TYPE P) passes into breast milk.

NOTE: As with many other drugs, certain advice to patients being treated with LISINOPRIL/HCTZ (TYPE P) is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

ADVERSE REACTIONS

In clinical trials involving 930 patients, including 100 patients treated for 50 weeks or more, the most severe clinical adverse reactions were syncope (0.8%), and hypotension (1.9%). The most frequent clinical adverse reactions were: dizziness (7.5%), headache (5.2%), cough (3.9%), fatigue (3.7%) and orthostatic effects (3.2%).

Discontinuation of treatment due to adverse reactions occurred in 4.4% of patients, mainly because of dizziness, cough, fatigue or muscle cramps.

Adverse reactions that have occurred in clinical trials or in marketing experience are those which have been previously reported with lisinopril and hydrochlorothiazide when used separately for the treatment of hypertension.

Adverse reactions occurring in hypertensive patients treated with lisinopril and hydrochlorothiazide in controlled trials are shown below.

	LISINOPRIL 2633 PATIENTS	**LISINOPRIL PLUS HYDROCHLOROTHIAZIDE 930 PATIENTS**
CARDIOVASCULAR		
Hypotension	1.4%	1.9%
Orthostatic effects	0.9%	3.2%
Chest pain	1.1%	1.0%
Syncope	0.2%	0.8%
Angina	0.3%	0.1%
Edema	0.6%	0.1%
Palpitation	0.8%	0.9%
Rhythm disturbances	0.5%	0.1%
Chest discomfort	-	0.6%
GASTROINTESTINAL		
Diarrhea	1.8%	2.5%
Nausea	1.9%	2.2%
Vomiting	1.1%	1.4%
Dyspepsia	0.5%	1.3%
Anorexia	0.4%	0.2%
Constipation	0.2%	0.3%
Flatulence	0.3%	0.2%
Abdominal pain	1.4%	0.9%
Dry mouth	0.5%	0.2%
NERVOUS SYSTEM		
Dizziness	4.4%	7.5%
Headache	5.6%	5.2%
Paresthesia	0.5%	1.5%
Depression	0.7%	0.5%
Somnolence	0.8%	0.4%
Insomnia	0.3%	0.2%
Vertigo	0.2%	0.9%
RESPIRATORY		
Cough	3.0%	3.9%
Dyspnea	0.4%	0.4%

	LISINOPRIL 2633 PATIENTS	LISINOPRIL PLUS HYDROCHLOROTHIAZIDE 930 PATIENTS
Upper respiratory infection	2.1%	2.2%
DERMATOLOGIC		
Rash	1.0%	1.2%
Pruritis	0.5%	0.4%
Flushing	0.3%	0.8%
Angioedema	0.1%	-*
MUSCULOSKELETAL		
Muscle cramps	0.5%	2.0%
Back pain	0.5%	0.8%
Shoulder pain	0.2%	0.5%
OTHER		
Fatigue	-	3.7%
Asthenia	2.7%	1.8%
Decreased libido	0.2%	1.0%
Fever	0.3%	0.5%
Impotence	0.7%	1.2%
Gout	0.2%	0.2%

*See lisinopril and hydrochlorothiazide (Marketing Experience Only)

Laboratory Test Findings

Hypokalemia, Hyperkalemia: (see PRECAUTIONS).

Creatinine, Blood Urea Nitrogen: Minor increases in blood urea nitrogen (3.8%) and serum creatinine (4.2%) were observed in patients with essential hypertension treated with lisinopril and hydrochlorothiazide. More marked increases have also been reported and were more likely to occur in patients with bilateral renal artery stenosis (see PRECAUTIONS).

Increases in blood urea nitrogen and serum creatinine, usually reversible upon discontinuation of therapy, were observed in 1.1 and 1.6% of patients respectively with essential hypertension treated with lisinopril alone.

Serum Uric Acid, Glucose, Magnesium, Cholesterol, Triglycerides and Calcium: (see PRECAUTIONS).

Hemoglobin and Hematocrit: Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.5 g percent and 1.5 vol percent, respectively) occurred frequently in hypertensive patients treated with lisinopril and hydrochlorothiazide but were rarely of clinical importance unless another cause of anemia coexisted. In clinical trials, 0.4% of patients discontinued therapy due to anemia.

Rarely, hemolytic anemia has been reported.

Agranulocytosis and bone marrow depression, manifested as anemia, thrombocytopenia or leucopenia, have been caused by angiotensin-converting enzyme inhibitors, including lisinopril.

Several cases of agranulocytosis and neutropenia have been reported in which a causal relationship to lisinopril cannot be excluded (see WARNINGS, Neutropenia/Agranulocytosis).

Other (Causal Relationship Unknown): Rarely, elevations of liver enzymes and/or serum bilirubin have occurred.

Adverse Reactions Reported in Uncontrolled Trials and/or Marketing Experience.

Lisinopril and hydrochlorothiazide tablets

Cardiovascular
Myocardial infarction or cerebrovascular accident possibly secondary to excessive hypotension in high risk patients (see WARNINGS).
Tachycardia

Dermatologic
Alopecia
Urticaria
Pruritus
Diaphoresis

Severe Skin Disorders
Erythema multiforme
Pemphigus
Stevens-Johnson syndrome
Toxic epidermal necrolysis

Gastrointestinal
Abdominal pain and indigestion
Dry mouth
Pancreatitis
Vomiting

Hematologic
Hemolytic anemia

Hepatic
Liver function abnormalities
Hepatitis
Jaundice (hepatocellular and/or cholestatic)

Nervous System
Mood alterations
Mental confusion
Paresthesia
Vertigo

Respiratory
Bronchospasm
Rhinitis
Sinusitis

Special Senses
Taste disorder

Urogenital
Uremia
Oliguria/anuria
Renal dysfunction
Acute renal failure
Impotence

A symptom complex has been reported which may include fever, vasculitis, myalgia, arthralgia/arthritis, a positive ANA, elevated ESR, eosinophilia, and leukocytosis. Rash, photosensitivity, or other dermatologic manifestations may also occur.

Lisinopril and hydrochlorothiazide tablets **(Marketing Experience Only)**

Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported (see WARNINGS).

In very rare cases, intestinal angioedema has been reported with angiotensin-converting enzyme inhibitors including lisinopril.

Cases of pancreatitis have been reported.

No other adverse events have been reported with lisinopril and hydrochlorothiazide which have not been reported with lisinopril or hydrochlorothiazide individually.

SYMPTOMS AND TREATMENT OF OVERDOSAGE

No specific information is available on the treatment of overdosage with Lisinopril and Hydrochlorothiazide. Treatment is symptomatic and supportive. Therapy with LISINOPRIL/HCTZ (TYPE P) should be discontinued and the patient observed closely. Suggested measures include induction of emesis and/or gastric lavage, if ingestion is recent, and correction of dehydration, electrolyte imbalance and hypotension by established procedures.

Lisinopril
The most likely features of overdosage would be hypotension, for which the usual treatment would be intravenous infusion of normal saline solution. Lisinopril may be removed from general circulation by hemodialysis.

Hydrochlorothiazide
The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias.

DOSAGE AND ADMINISTRATION

Dosage must be individualized. The fixed combination is not for initial therapy. The dose of LISINOPRIL/HCTZ (TYPE P) should be determined by the titration of the individual components.

Once the patient has been successfully titrated with the individual components as described below, either one LISINOPRIL/HCTZ (TYPE P) 10/12.5 mg or, one or two 20/12.5 mg or 20/25 mg tablets once daily may be substituted if the titrated doses are the same as those in the fixed combination (see INDICATIONS AND CLINICAL USE and WARNINGS).

Patients usually do not require doses in excess of 50 mg of hydrochlorothiazide daily, particularly when combined with antihypertensive agents.

For lisinopril monotherapy the recommended initial dose in patients not on diuretics is 10 mg of lisinopril once a day. Dosage should be adjusted according to blood pressure response. The usual dosage range of lisinopril is 10 to 40 mg administered in a single daily dose. The antihypertensive effect may diminish toward the end of the dosing interval regardless of the administered dose, but most commonly with a dose of 10 mg daily. This can be evaluated by measuring blood pressure just prior to dosing to determine whether satisfactory control is being maintained for 24 hours. If it is not, an increase in dose should be considered. The maximum dose used in long term controlled clinical trials was 80 mg/day. If blood pressure is not controlled with lisinopril alone, a low dose of a diuretic may be added. Hydrochlorothiazide 12.5 mg has been shown to provide an additive effect. After the addition of a diuretic, it may be possible to reduce the dose of lisinopril.

Diuretic Treated Patients
In patients who are currently being treated with a diuretic, symptomatic hypotension occasionally may occur following the initial dose of lisinopril. The diuretic should, if possible, be discontinued for two to three days before beginning therapy with lisinopril to reduce the likelihood of hypotension (see WARNINGS). The dosage of lisinopril should be adjusted according to blood pressure response. If the patient's blood pressure is not controlled with lisinopril alone, diuretic therapy may be resumed as described above.

If the diuretic cannot be discontinued, an initial dose of 5 mg of lisinopril alone should be administered and the patient remain under medical supervision for at least two hours, and until blood pressure has stabilized for at least an additional hour (see WARNINGS and PRECAUTIONS, Drug Interactions).

Dosage Adjustment in Renal Impairment
In patients with creatinine clearance greater than 30 mL/min, the usual dose titration of the individual components is required.

For patients with creatinine clearance between 10 and 30 mL/min, the starting dose of lisinopril is 2.5 - 5.0 mg/day. The dosage may then be titrated upward until blood pressure is controlled or to a maximum of 40 mg daily.

When concomitant diuretic therapy is required in patients with moderate or severe renal impairment (creatinine clearance < 30 mL/min), a loop diuretic, rather than a thiazide diuretic is preferred for use with lisinopril. Therefore, for patients with moderate or severe renal dysfunction the lisinopril-hydrochlorothiazide combination tablet is not recommended (see PRECAUTIONS - Renal Impairment, Anaphylactoid Reactions during Membrane Exposure).

PHARMACEUTICAL INFORMATION

DRUG SUBSTANCE

Drug Substance: Lisinopril

Common name: Lisinopril

Chemical Name: 1-[N^2-[(S)-1-Carboxy-3-phenylpropyl]-L-lysyl]-L-proline dihydrate

Structural Formula:



Molecular Formula: $C_{21}H_{31}N_3O_5 \cdot 2H_2O$

Molecular Weight: 441.52

Description: Lisinopril is a white to off-white, crystalline powder. It is soluble in water, sparingly soluble in methanol and practically insoluble in acetone and in ethanol.

Drug Substance: Hydrochlorothiazide

Common name: Hydrochlorothiazide

Chemical name:
1. 2H-1,2,4-Benzothiadiazine-7-sulfonamide,6-chloro-3,4-dihydro-,1,1-dioxide
2. 6-Chloro-3,4 dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide

Structural Formula:



Molecular Formula: $C_7H_8ClN_3O_4S_2$

Molecular Weight: 297.74

Description: Hydrochlorothiazide is a white to off-white, crystalline powder. It practically insoluble in water, but freely soluble in sodium hydroxide solution.

COMPOSITION

Each LISINOPRIL/HCTZ (TYPE P) tablet contains corn starch, dibasic calcium phosphate, magnesium stearate, mannitol, pregelatinized corn starch, FD & C Blue #2 Aluminum Lake (10/12.5 mg tablet), yellow iron oxide (20/12.5 mg and 20/25 mg tablet) and red iron oxide (20/25 mg tablet).

STABILITY AND STORAGE RECOMMENDATIONS

Store between 15°C - 30°C. Protect from light and moisture.

AVAILABILITY OF DOSAGE FORMS

LISINOPRIL/HCTZ (TYPE P) 10 mg/12.5 mg are blue, hexagon-shaped, biconvex tablets, engraved with **N** on one side and **10/12.5** on the other side. Each tablet contains 10 mg of lisinopril (as lisinopril dihydrate) and 12.5 mg of hydrochlorothiazide. Available in bottles of 100 and blister pack boxes of 30.

LISINOPRIL/HCTZ (TYPE P) 20 mg/12.5 mg are yellow, hexagon-shaped, scored tablets, engraved with **N** on one side and **20** over scoreline **12.5** on the other side. Each tablet contains 20 mg of lisinopril (as lisinopril dihydrate) and 12.5 mg of hydrochlorothiazide. Available in bottles of 100 and blister pack boxes of 30.

LISINOPRIL/HCTZ (TYPE P) 20 mg/25 mg are peach, hexagon-shaped scored tablets, engraved with **N** on one side and **20**/**25** on the other side. Each tablet contains 20 mg of lisinopril (as lisinopril dihydrate) and 25 mg of hydrochlorothiazide. Available in bottles of 100 and blister pack boxes of 30.

CLINICAL TRIALS

A blinded, single dose, randomized, three-period, six-sequence, three-treatment, crossover study between Lisinopril/Hydrochlorothiazide 20 mg/ 12.5 mg Tablets (Sanis Health Inc., Canada) and Prinzide® 20 mg/ 12.5 mg Tablets (Merck Frosst Canada & Co.) in 35 healthy subjects (male and female) under fasting conditions. A second reference product (Zestoretic®) was administered but not included in the statistical analysis presented in the following summary tables.

Lisinopril (1 x 20 mg /12.5 mg) From measured data **uncorrected for potency** Geometric Mean Arithmetic Mean (CV %)				
[+]Parameter	* LISINOPRIL/HCTZ 20 mg / 12.5 mg tablet	[s] Prinzide® 20 mg / 12.5 mg tablet AstraZeneca Canada Inc.	[a] % Ratio of Geometric Means	[a] 90% Confidence Interval
AUC_{0-72} (ng.h/mL)	1351.09 1443.99 (38)	1424.94 1527.96 (37)	94.82	89.16 – 100.83
C_{max} (ng/mL)	92.70 100.30 (40)	98.18 106.45 (40)	94.41	88.06 – 101.22
T_{max}[§] (h)	6.01 (20)	6.04 (20)		

* LISINOPRIL/HCTZ 20 mg / 12.5 mg Tablets (Sanis Health Inc., Canada)

s Prinzide® 20 mg / 12.5 mg Tablets (Merck Frosst Canada & Co.) were purchased in Canada

§ Expressed as the arithmetic mean (CV%) only

[a] Based on least-squares mean estimates.

\+ Due to the design of the study, meaningful AUC_I and $T_{½}$ parameters could not be calculated.

Hydrochlorothiazide (1 x 20 mg / 12.5 mg) From measured data **uncorrected for potency** Geometric Mean Arithmetic Mean (CV %)				
Parameter	* LISINOPRIL/HCTZ 20 mg / 12.5 mg tablet	[s] Prinzide® 20 mg / 12.5mg tablet AstraZeneca Canada Inc.	[a] % Ratio of Geometric Means	[a] 90% Confidence Interval
AUC_T (ng.h/mL)	752.046 776.753 (27)	755.711 787.998 (30)	99.52	96.27 - 102.87
AUC_{inf} (ng.h/mL)	768.009 793.508 (27)	770.992 804.097 (30)	99.61	96.38 - 102.96
C_{max} (ng/mL)	113.190 118.611 (31)	109.315 115.403 (34)	103.55	97.03 - 110.50
T_{max} [§] (h)	1.83 (32)	2.08 (37)		
$T_{½}$ [§] (h)	9.26 (12)	9.05 (12)		

* LISINOPRIL/HCTZ 20 mg / 12.5 mg Tablets (Sanis Health Inc., Canada)

s Prinzide® 20 mg / 12.5 mg Tablets (Merck Frosst Canada & Co.) were purchased in Canada

§ Expressed as the arithmetic mean (CV%) only

[a] Based on least-squares mean estimates.

A blinded, single dose, randomized, three-period, six-sequence, three-treatment, crossover study between Lisinopril/Hydrochlorothiazide 20 mg/ 25 mg Tablets (Sanis Health Inc., Canada) and Prinzide® 20 mg/ 25 mg Tablets (Merck Frosst Canada & Co.) in 36 healthy subjects (male and female) under fasting conditions. A second reference product (Zestoretic®) was administered but not included in the statistical analysis presented in the following summary tables.

Lisinopril (1 x 20 mg / 25 mg) From measured data **uncorrected for potency** Geometric Mean Arithmetic Mean (CV %)				
+Parameter	* LISINOPRIL/HCTZ 20 mg / 25 mg tablet	s Prinzide® 20 mg / 25 mg tablet AstraZeneca Canada Inc.	% Ratio of Geometric Means	90% Confidence Interval
AUC_{0-72} (ng.h/mL)	1350.48 1382.20 (21)	1280.00 1326.72 (28)	105.51	98.10 - 113.47
C_{max} (ng/mL)	93.89 96.73 (24)	87.85 91.94 (31)	106.87	97.89 - 116.68
T_{max} § (h)	6.13 (17)	6.46 (18)		

* LISINOPRIL/HCTZ 20 mg / 25 mg Tablets (Sanis Health Inc., Canada)

s Prinzide® 20 mg / 25 mg Tablets (Merck Frosst Canada & Co.) were purchased in Canada

§ Expressed as the arithmetic mean (CV%) only

\+ Due to the design of the study, meaningful AUC_I and $T_{½}$ parameters could not be calculated.

Hydrochlorothiazide (1 x 20 mg / 25 mg) From measured data **uncorrected for potency** Geometric Mean Arithmetic Mean (CV %)				
Parameter	* LISINOPRIL/HCTZ 20 mg / 25 mg tablet	[s] Prinzide® 20 mg / 25mg tablet AstraZeneca Canada Inc.	% Ratio of Geometric Means	90% Confidence Interval
AUC_T (ng.h/mL)	1493.462 1523.506 (20)	1412.585 1453.226 (24)	105.73	101.93 - 109.66
AUC_{inf} (ng.h/mL)	1524.107 1554.848 (20)	1442.378 1483.998 (24)	105.67	101.99 - 109.47
C_{max} (ng/mL)	233.350 241.694 (28)	201.664 212.139 (33)	115.71	108.07 - 123.90
T_{max} [§] (h)	1.92 (50)	2.29 (43)		
$T_{½}$ [§] (h)	9.13 (10)	9.23 (11)		

* LISINOPRIL/HCTZ 20 mg / 25 mg Tablets (NT Pharma Canada Limited, Canada)

s Prinzide® 20 mg / 25 mg Tablets (Merck Frosst Canada & Co.) were purchased in Canada

§ Expressed as the arithmetic mean (CV%) only

INFORMATION FOR THE PATIENT

[Pr]LISINOPRIL/HCTZ (TYPE P) Tablets

LISINOPRIL/HCTZ (TYPE P) is the brand name for NT Pharma Canada Limited for the combination of the substances - lisinopril and hydrochlorothiazide. Lisinopril is one of a class of medicines known as angiotensin-converting enzyme inhibitors and hydrochlorothiazide is a thiazide diuretic, often termed a "water pill". This combination is available **only on prescription** from your physician. It is usually prescribed to reduce **high blood pressure**.

When blood pressure is high, the workload of the heart and arteries increases so that over time, these may not function as they should. In turn, this could lead to damage of the "vital organs": brain - heart - kidneys, and result in stroke, heart failure, heart attack, blood vessel disease or kidney disease.

Remember - This medicine is prescribed for the particular condition that you have. **Do not give this medicine to other people, nor use it for any other condition.**

Do not use outdated medicine.

Keep all medicines out of the reach of children.

Read the following information carefully. **If you need any explanations, or further information, ask your physician or pharmacist.**

BEFORE TAKING THIS MEDICINE

Serious Warnings and Precautions

LISINOPRIL/HCTZ (TYPE P) should not be used during pregnancy. If you discover that you are pregnant taking LISINOPRIL/HCTZ (TYPE P), stop the medication and please contact your physician as soon as possible.

This medicine may not be suitable for certain people. So, tell your physician if you think any of the following applies to you:

- You have previously taken **any** of the following and were allergic or reacted badly to it: hydrochlorothiazide or any other diuretic or "water pill"; sulfonamides (sulfa medicine); lisinopril or any other medication of the same type – angiotensin-converting enzyme (ACE) inhibitors with the names usually ending with 'pril' such as lisinopril, enalapril, captopril, particularly if you experienced swelling of the face, lips, tongue, or throat, or had sudden difficulty breathing or swallowing. You should not take LISINOPRIL/HCTZ (TYPE P) if you have had these types of reactions without a known cause or if you have been diagnosed with hereditary or idiopathic angioedema.

- **You are pregnant, breast-feeding or thinking of becoming pregnant**. Taking LISINOPRIL/HCTZ (TYPE P) during pregnancy can cause injury and even death to your developing baby. This medicine should not be used during pregnancy. If you become pregnant while taking LISINOPRIL/HCTZ (TYPE P), stop the medication and report to your physician as soon as possible. It is possible that LISINOPRIL/HCTZ (TYPE P) passes into breast milk. You should not breast-feed while taking LISINOPRIL/HCTZ (TYPE P).

- You have any of these conditions:
  - diabetes
  - heart or blood vessel disease
  - liver disease
  - kidney disease, or difficulty in producing urine
  - bronchial asthma
  - lupus erythematosus or a history of this condition
  - gout or history of gout

Your physician also needs to know if you are taking any other medication, whether they be prescription medications or over-the-counter products. It is particularly important to inform your physician if you are taking:

- Diuretics or "water pills"; any other medicines to reduce blood pressure; potassium-containing medicines, potassium supplements, or salt substitutes that contain potassium; insulin for diabetes; lithium (a drug used to treat a certain kind of depression) or anti-inflammatory medicines used in arthritis.

You should also inform your physician if you are vomiting or have severe diarrhea.

This medicine is not recommended for children.

PROPER USE OF THIS MEDICINE

- Take this medicine exactly as your physician ordered.

- The absorption of this medicine is not affected by food; so it can be taken with or without a meal.

- Try to take your medicine every day at the same time. This way it becomes easy to remember your doses.

- If you miss a dose of this medicine, take it as soon as possible. However, if no more than six hours have elapsed since the missed dose, you may take that day's dose of medication and then go back to your regular dosing schedule. **Do not take a double dose.**

- In case of an overdose, contact your physician immediately so that medical attention may be given promptly. The most likely symptom would be a feeling of lightheadedness or dizziness due to a sudden or excessive drop in blood pressure.

- If your physician has recommended a particular diet, for instance less salt, follow the diet carefully. This could help your medicine to control your blood pressure. Your physician may also recommend weight loss. Do follow these suggestions.

- This medicine does not cure high blood pressure, **but does help control it**. So, it is important to continue taking the tablets regularly to keep your blood pressure down. You may have to take high blood pressure medicine for life.

- Keep your regular appointments with your physician, even if you feel well. High blood pressure may not be easily recognized by you, because you may not "feel any symptoms"; but your physician can measure your pressure very easily, and check how the medicine is controlling it.

- **Do not take any other medicines** unless you have discussed the matter with your physician. Certain medications tend to increase your pressure, for example, non-prescription preparations for appetite control, asthma, colds, coughs, hay fever and sinus problems.

- If you have to undergo any dental or other surgery, inform the dentist or the physician in charge that you are taking this medicine.

- Store your tablets at 15°C - 30°C in a tightly closed container, away from heat and direct light, and out of damp places, such as the bathroom or kitchen.

SIDE EFFECTS OF THIS MEDICINE - AND WHAT YOU SHOULD DO

Along with its intended action, any medication, including lisinopril with hydrochlorothiazide, may cause side effects. Most people do not experience any problem when taking this medicine; but if you notice any of the following, medical attention may be needed.

- Sudden difficulty in breathing or swallowing
- Swelling of face, eyes, lips, tongue and/or throat, hands or feet. You should be aware that black patients are at increased risk of these types of reactions to ACE inhibitors
- Dizziness, lightheadedness or fainting following exercise, and/or when it is hot and you have lost a lot of water by sweating
- Flu-like symptoms such as fever, malaise, muscle pain, rash, itching, abdominal pain, nausea, vomiting, diarrhea, jaundice, loss of appetite

STOP TAKING THE MEDICATION AND CONTACT YOUR PHYSICIAN OR PHARMACIST AT ONCE. YOU MAY REQUIRE IMMEDIATE CARE. IF CONDITION WORSENS, SEEK MEDICAL ATTENTION.

- **If any fainting occurs, stop taking the medicine. If dizzy, avoid driving or any activity/jobs requiring alertness. Use extra care during exercise or hot weather.**

- **You may experience increased skin sensitivity to sunlight. Avoid too much sunlight and do not use a sunlamp**.

- Dry cough, sore throat
- Unusual tiredness and/or weakness
- Chest pain
- Impotence
- Headache
- Palpitations
- Tingling of the skin
- Less or no urine being produced

IF YOU NOTICE ANY OF THE ABOVE OR HAVE OTHER SIDE EFFECTS, CONTACT YOUR PHYSICIAN OR YOUR PHARMACIST. IF THE CONDITION PERSISTS OR WORSENS, SEEK MEDICAL ATTENTION.

INGREDIENTS

Active ingredient: Each blue tablet of LISINOPRIL/HCTZ (TYPE P) 10/12.5 mg contains 10 mg of lisinopril and 12.5 mg of hydrochlorothiazide. Each yellow tablet of LISINOPRIL/HCTZ (TYPE P) 20/12.5 mg contains 20 mg of lisinopril and 12.5 mg of hydrochlorothiazide. Each peach tablet of LISINOPRIL/HCTZ (TYPE P) 20/25 mg contains 20 mg of lisinopril and 25 mg of hydrochlorothiazide.

Non-medicinal ingredients: Each LISINOPRIL/HCTZ (TYPE P) contains corn starch, dibasic calcium phosphate, magnesium stearate, mannitol, pregelatinized corn starch, FD & C Blue #2 Aluminum Lake (10/12.5 mg tablet), yellow iron oxide (20/12.5 mg and 20/25 mg tablet) and red iron oxide (20/25 mg tablet).

PHARMACOLOGY

Lisinopril

Study	Species/strain	Number of Animals/Group	Route	Dose	Results
MECHANISM OF ACTION					
In vitro ACE inhibitory activity*	Hog plasma		*In vitro*		IC_{50} = 1.7 ± 0.5 nM
Augmentation of contractile response to bradykinin	Guinea pig ileum	7 segments	*In vitro*		AC_{50} = 1.6 nM
In vivo ACE inhibition in the rat**	Male Sprague/Dawley	8	I.V.		ID_{50} = 2.3 (1.7 - 3.1) µg/kg
Duration of ACE inhibitory activity of lisinopril in rats**	Male Sprague/Dawley	4	I.V.	3 & 10 µg/kg	Duration approx. 110 min.
In vivo ACE inhibitory activity of lisinopril in conscious rats**	Sprague/Dawley	3 - 5	P.O.	0.03 - 3.0 mg/kg (single dose)	Duration of at least 360 min.
In vivo ACE inhibition in anesthetized dogs**	Mongrel	6	I.V.	1 - 30 µg/kg	ID_{50} = 6.5 µg/kg
In vivo ACE inhibitory activity of lisinopril in conscious dogs**	Mongrel	3	P.O.	0.05 - 1.0 mg/kg (single dose)	Duration of action of between 6 - 24 hours
EFFECTS ON BLOOD PRESSURE					
Antihypertensive activity in renal hypertensive dogs (single doses)	Mongrel	3	P.O.	0.3 mg/kg with and without hydrochloro -thiazide	After 2 hours: Lisinopril alone: 5% reduction in mean systolic pressure vs pretreatment. Lisinopril + Hydrochlorothiazide = 11% reduction in mean systolic pressure vs pretreatment.
Antihypertensive activity in rats on a sodium-deficient diet (single doses)	Male Sprague/Dawley	5	P.O.	0.03-3.0 mg/kg daily for 4 days	After 2 hours: 11% reduction in mean systolic pressure vs pretreatment at 1 mg/kg. 22% reduction in mean systolic pressure vs pretreatment at 3 mg/kg. Consistent response over 4 days.
Antihypertensive activity in 2 kidney Grollman hypertensive rats (single doses)	Male Sprague/Dawley	6 - 7	P.O.	1 & 3 mg/kg	At 2 hours: approx. 6% reduction in mean systolic pressure vs pretreatment with the antihypertensive effect lasting up to 24 hours.
Antihypertensive activity in spontaneous hypertensive rats with and without hydrochlorothiazide	SH rats	3 - 6	P.O.	1.25 mg/kg HCTZ = 50 mg/kg daily for 3 days	Enhancement of hypotensive activity over 3 - 5 days. Two hours after drug administration, lisinopril alone reduced the average mean arterial pressure from 198 to 161 mmHg, In combination with Hydrochlorothiazide, the average mean arterial pressure was reduced from 202 to 132 mmHg.
Antihypertensive activity in spontaneously	SH rats	3 - 9	P.O. & I.V.	0.1 – 20 mg/kg	Slight fall in blood pressure at 0.312 - 5 mg/kg P.O. Pronounced fall at 20 mg/kg P.O. and 0.1 mg/kg

hypertensive rats (single doses)					I.V. with statistically significant reductions being observed for the majority of time points between ½ - 18 hours.

* Inhibition of enzymatic activity of hog plasma ACE using ^{14}C labeled substrate.

** Blockage of functional (pressor) response to AI challenge.

Lisinopril and Hydrochlorothiazide

In spontaneously hypertensive rats (SHR) lisinopril was studied in an oral dose of 1.25 mg/kg daily, given alone or concomitantly with hydrochlorothiazide 50 mg/kg orally, for 3 days. Reductions in blood pressure were recorded (tail cuff method) on each of the 3 treatment days, reaching normotensive levels (113 - 116 mmHg) on Day 3 at 4 - 8 hours after the concomitant therapy.

TOXICOLOGY

Acute Toxicity of Lisinopril

LD_{50} Values:

Species	Sex	Route	LD_{50} (g/kg)
Mouse	Male	Oral	>20
Mouse	Female		>20
Rat	Male		>20
Rat	Female		>20
Dog	Male		>6
Dog	Female		>6
Mouse	Male	Intravenous	>10
Mouse	Female		>10
Rat	Male	Intraperitoneal	>10
Rat	Female		>10

Signs of toxicity: Following oral administration to mice decreased activity and one male death (1/10) occurred. No signs of toxicity occurred in rats after oral administration. Dogs given 6 g/kg had transient diarrhea and increases in serum urea nitrogen. Intravenous administration to mice produced bradypnea, ataxia, clonic convulsions, exophthalmia, and tremors. After intraperitoneal administration in rats, ataxia and one female death (1/10) occurred. No signs of toxicity or death occurred in the males.

Subacute/Chronic Toxicology (lisinopril)

Species	Duration	No. of Animals/Group	Route	Dose mg/kg/day	Results
Rat	2 week	10 F + 10 M	Oral	3, 10, 30	At all doses, decreases of 2 to 16% in weight gain and 12 to 14% in heart weights were observed in female rats.
Rat	3 month with 1 month interim	25 F + 25 M	Oral	3, 10, 30	At all doses, increased serum urea nitrogen values (up to approximately 2-fold) and decreased heart weights (7 to 10%) were observed in female rats. At 10 and 30 mg, respectively, weight gain decreased 11 to 14% in males. An increased incidence of focal erosions of the gastric mucosa and focal renal tubular basophilia were also seen.
Rat	1 year with 6 month interim	25 F + 25 M	Oral	2, 5, 10, 30, 90[a]	At all doses, a decrease in weight gain (up to 16%) was observed; serum urea nitrogen increased up to 4-fold; serum sodium decreased (average down to 3 mEq/L) and serum potassium increased (average up to 0.5 mEq/L). At 2, 5, 10 and 30 mg, heart weight decreased; at 5, 10 and 30 mg, kidney weight increased; and at 5, 10, 30 and 90 mg, renal tubular basophilia increased. At 10, 30 and 90 mg, focal interstitial nephritis was observed.
Rat	3 month with a 1 month interim and a 1 month recovery	30 F + 30 M	Oral	3, 30, 300, 3000	At all doses, weight gain decreased by 5 to 11% and increases were observed in serum urea nitrogen (up to approximately 3-fold) and serum potassium (average up to 0.4 mEq/L). At 30, 300 and 3000 mg there was an increased incidence of focal renal tubular basophilia and focal necrosis of the glandular mucosa of the stomach. An increased incidence of focal tubular basophilia persisted in rats given 300 or 3000 mg/kg/day.
Rat	1 month	15 F + 15 M	Oral	30, 60 30, 60 (with saline)	Saline supplementation prevented decreased weight gain and elevations in serum urea nitrogen at 30 and 60 mg. Decreases in cardiac weight at 30 and 60 mg were suppressed by saline supplementation in males at 30 mg. At 30 and 60 mg, renal changes produced due to a low salt diet (renal tubular degeneration and renal tubular basophilia) were prevented by saline supplementation. Mild gastric erosions or necrotic changes were seen in 1 or 2 of 30 rats given 30 or 60 mg. These gastric changes were not seen in saline supplemented animals given these doses; however, the relationship of amelioration due to saline is uncertain because of the low incidence of this change, which is also occasionally seen in untreated animals.
Rat	5 day 6 day recovery	8 M	Oral	5, 300	Consumption of 2% saline increased during treatment at 5 mg and on Days 2 to 4 post-treatment at 300 mg.
Dog	2 week	3 F + 3 M	Oral	3, 10, 30	At 30 mg, mineralization of the papilla muscle of the heart was seen in 1 of 6 dogs.
Dog	3 month with 1 month interim	5 F + 5 M	Oral	3, 10, 30	At 10 mg, hemoglobin concentration, hematocrit, and erythrocyte count decreased in 2 dogs. Marked increases in serum urea nitrogen and creatinine were observed in 2 of 10 dogs. One of these dogs had marked renal tubular degeneration and ulcers of the tongue, gums and gastric pyloric mucosa related to uremia. At 30 mg, there was an increase in serum urea nitrogen (average up to 2-fold) and a decrease in serum sodium (down to 4 mEq/L) and serum chloride (down to 3 mEq/L). At 10 and 30 mg, average cardiac weight was decreased (13 to 15%).

[a] Dosing terminated Week 11, rats killed Week 27.

Species	Duration	No. of Animals/Group	Route	Dose mg/kg/day	Results
Dog	1 year with 6 month interim	5 F + 5 M	Oral	3, 5, 15	At 15 mg, increases were observed in serum urea nitrogen (less than 2-fold). Decreases in serum sodium (average down to 2 mEq/L) and increases in serum potassium (average up to 0.5 mEq/L) occurred at all doses.
Dog	18 day	3 F + 3 M	Oral	60/90 with and without saline	Saline supplementation prevented increases in serum urea nitrogen in dogs given 60 mg for 8 days followed by 90 mg for 8 or 9 days.
Dog	7 day	4 F + 4 M	I.V.	60, 90	Decreases in blood pressure and increases in serum urea nitrogen occurred in dogs given 60 or 90 mg/kg/day. Supplementation with physiologic saline (25 mL/kg one hour prior to dosing and 4 hours after dosing) prevented these changes. Increased serum potassium (average up to 0.6 mEq/L) and decreased serum chloride (average down to 0.4 mEq/L) values were seen in both supplemented and unsupplemented animals.
Dog	1 month	2 F + 2 M	Oral	3, 30, 300 and 1000	At 30 mg or greater, BUN increased and specific gravity of the urine decreased. Hyperplasia of renal epithelial cells was observed and deaths occurred. Dogs that died had dilation of distal renal tubules and fatty degeneration of renal tubular epithelium. No drug-related effects were observed at 3 mg.
Dog	3 month with 1 month recovery (high dose)	Control 5 M + 5 F 3, 10, 30 mg/kg/day 3 M + 3 F 100 mg/kg/day 8 M + 8 F Recovery control 2 M + 2 F 100 mg/kg/day 5 M + 5 F	Oral	3, 10, 30 and 100	Eight of 16 dogs given 100 mg died or were killed because of poor physical condition. One of 6 dogs given 30 mg was killed because of poor physical condition. At 10 mg or greater increased BUN and dilation of renal tubules was seen. Fatty degeneration of renal tubular epithelium occurred at the 2 highest dosage levels. The changes are reversible as only slight dilation of renal tubules was present in some animals given 100 mg after 4 weeks of recovery.
Rabbit	2 week	6 F	Oral	15 (1, 6 and 13 doses) with and without saline	Renal tubular basophilia and renal tubular dilation (considered sequela to necrosis) were seen after 6 and 13 doses in unsupplemented rabbits. Two supplemented rabbits (6 doses) also had the same renal lesion. One rabbit drank very little saline and had increases in BUN, creatinine and potassium. Increases in these parameters were seen in unsupplemented animals after 1, 6, and 13 doses.

Teratology Studies (Lisinopril)

Species	No of Animals/Group	Dose mg/kg/day	Route	Duration of Dosing	Results
Mice	25	100, 300, 1000, 1000 with saline	Oral	Day 6 through Day 15 of gestation	No teratogenic effect was observed. There was an increased incidence of resorptions in all unsupplemented groups (no increase in serum urea nitrogen).
Rat	35	30, 100, 300, 300 with saline	Oral	Day 6 through Day 17 of gestation	No teratogenic effect was observed. Maternal weight gain decreased in all unsupplemented groups. The open field behavioral test (measure of spontaneous activity) showed increased activity in Week 5 postpartum F1 females at 300 mg with and without saline, but only in 300 mg with saline females in Week 6. When the open field test was repeated in males and females given 300 mg with and without saline in Week 11 no increase in activity was seen.
Rabbit (New Zealand)	18	0.1, 0.3, 1.0 all groups with saline	Oral	Day 6 through Day 18 of gestation	No teratogenic effect was observed. At all doses there was an increased incidence of incomplete ossification (sternebrae, metacarpals, forefoot phalanges, pelvic bones, and tali and/or calcanea) which was considered to represent a fetotoxic effect. At 1 mg one rabbit had a high incidence of resorptions.
Rabbit (New Zealand)	18	0.031, 0.125, 0.5	Oral	Day 6 through day 18 of gestation	No fetotoxicity or embryotoxicity was observed at maternotoxic doses. At 0.125 and 0.5 mg maternal deaths, decreased maternal weight gain and food consumption, as well as increases in BUN, creatinine and potassium were seen. In addition, doses of 0.5 mg produced decreases in serum sodium and chloride, diffuse distention of the renal distal tubules and degeneration of renal tubules.

Fertility and Late Gestation and Lactation with Postnatal Evaluation Studies (Lisinopril)

Species	No of Animals/Group	Dose mg/kg/day	Route	Duration of Dosing	Results
Rat	24 F & 24 M	30, 100, 300, 300 with saline	Oral	Males were dosed for 78 days prior to mating and females from 15 days prior to mating until sacrifice on Day 20 of gestation	Weight gain was reduced in unsupplemented males at all doses and during gestation in unsupplemented females. No effects on fertility and no signs of teratogenicity were observed. There was an increase in F1 pup deaths (3 to 8% vs. control 1%) Day 1 to 7 postpartum in 100 and 300 mg (saline and nonsaline) groups. Decreased mean F1 pup weight (3 to 7% less than controls) on Day 0 postpartum was seen in all unsupplemented groups.
Rat	20 F	30, 100, 300, 300 with saline	Oral	Day 15 of gestation through Day 21 post-partum	On Days 2 to 7 postpartum, there was an increased number of dead pups (8 to 10% vs. control 0%). On Day 21 postpartum, a decrease in pup weights (8% less than controls) was observed in the unsupplemented 100 and 300 mg groups. There was no effect in the supplemented group. Pup development was not altered.

Genotoxicity Studies (Lisinopril)

Study	Test System	Dose	Results
Mutagenesis			
Microbial mutagen with and without metabolic activation	*Salmonella typhimurium* TA1535, TA1537, TA98, TA100 *Escherichia coli* WP2, WP2 uvrA	Up to 2000 µg/plate Up to 10 mg/plate	Negative for mutagenic potential
In vitro V-79 mammalian cell mutagenesis with and without metabolic activation	Chinese Hamster Lung Cell	Up to 10 mM (4.42 mg/mL)	Negative for mutagenic potential
DNA Damage			
In vitro alkaline elution	Rat Hepatocyte	Up to 30 mM (13.25 mg/mL)	Negative for induction of DNA single strand breaks
Chromosomal Evaluation			
In vitro chromosomal aberration assay with and without metabolic activation	Chinese Hamster Ovary	Up to 30 mM (13.25 mg/mL)	Negative for induction of chromosomal aberration
In vivo chromosomal aberration assay	Bone Marrow Cells of Male Mice	Up to 5000 mg/kg	Negative for increases in chromosomal aberrations

Carcinogenicity Studies (Lisinopril)

Species	Duration	No of Animals/Group	Route	Dose mg/kg/day	Results
Mice Crl:CD-1(ICR)BR	92 week	50 F & 50 M	Oral	15, 45, 135 mg/kg/day	No evidence of carcinogenic effect was observed. Decreased weight gain (7 to 15%) was seen in females at 135 mg. A greater incidence and severity of chronic nephritis in females and males given 45 and 135 mg was also seen.
Rats Crl:CD(SD)BR	105 week	50 F & 50 M	Oral	10, 30, 90 mg/kg/day	No evidence of carcinogenic effect was observed. Decreased weight gain (5 to 14%) in male drug-treated rats during the first 67 weeks of the study was observed. Focal sacculations of the retinal vessels was more prevalent in rats given 30 or 90 mg than in controls in Drug Week 100. An increased incidence of renal tubular hypertrophy in drug-treated males at termination of study was seen (1 mg was considered the no-effect dose for this change in males based on an additional 105-week study at 1, 3, and 10 mg/kg/day). An increased incidence of chronic nephritis in drug-treated females (10 mg is the no-effect dose based on an additional 105-week study at 1, 3, and 10 mg/kg/day) was observed.

Toxicology (Lisinopril and Hydrochlorothiazide)

Species	Duration	No of Animals/Group	Route	Dose mg/kg/day	Effects
Rat	2 week	10 M + 10 F	Oral	Lisinopril 0, 3, 10, 30 mg/kg/day; Lisinopril/Hydrochlorothiazide 3/10, 10/10, 30/10 mg/kg/day	Decreased body weight gain was seen in all the drug-treated groups. A decrease in serum chloride occurred in all groups given the combination. Increased serum urea nitrogen occurred in the 2 highest groups given the combination. Renal tubular degeneration and gastritis or gastric ulcer occurred in one rat each at 10/10 and 30/10 mg/kg/day. An additional rat at 30/10 mg/kg/day also had a gastric ulcer without renal lesions. Decreased average heart weight (females) was seen in all the groups given the combination.
Rat	14 week	25 M + 25 F	Oral	Toxicity study with one month interim necropsy Lisinopril/ Hydrochlorothiazide 0/0, 3/10, 10/10, 30/10 mg/kg/day	Decreased body weight gain, increased serum urea nitrogen, decreased serum sodium and chloride, and decreased average heart weights occurred at all dosage levels. Very slight focal necrosis of the fundic mucosa of the stomach occurred in the 2 highest dosage groups. Focal renal tubular basophilia occurred at a higher incidence in drug-treated animals compared to control animals.
Rat	27 week	15 M + 15 F	Oral	Lisinopril/Hydrochlorothiazide 0/0, 3/10, 10/10, 30/10 mg/kg/day	All animals had average body weight gains approximately 5 to 25% below the controls throughout the study. Average serum urea nitrogen values were generally two to three times greater in drug-treated animals compared to controls. Other serum biochemical parameters changed very slightly. Decreases in erythrocyte parameters were seen at all dosage levels. Decreases in heart weight occurred at all dosage levels and increase in kidney weight occurred at the 2 highest dosage levels. Mineralization of the renal cortico-medullary junction occurred in 2 to 5 rats in each of the drug-treated groups. Very small or small necrotic foci of gastric mucosa occurred in 5 rats in the high dose group. Chronic nephritis and its early stage of renal tubular basophilia occurred among treated and control rats, but occurred at a greater incidence in treated rats.
Dog	2 week	3 M + 3 F	Oral	Lisinopril 0, 3, 10, 30 mg/kg/day; Lisinopril/Hydrochlorothiazide 3/10, 10/10, 30/10 mg/kg/day	Average body weight losses in dogs given lisinopril 30 mg/kg/day or lisinopril 10 or 30 mg/kg/day with hydrochlorothiazide were probably related to treatment. Increases in serum urea nitrogen, creatinine and phosphorus occurred at the 2 highest dosage levels of the combination. At these doses renal tubular degeneration and secondary lymphoid depletion and gastrointestinal lesions were seen. At the highest dose increases in SGPT, alkaline phosphatase, potassium, and calcium and

Species	Duration	No of Animals/Group	Route	Dose mg/kg/day	Effects
					decreases in serum chloride, necrosis of hepatocytes, and mineralization of the papillary muscle of the heart were seen.
Dog	14 week	5 M + 5 F	Oral	Toxicity study with one month interim necropsy Lisinopril/Hydrochlorothiazide 0/0, 1/10, 3/10, 10/10 mg/kg/day	3 dogs given 10/10 mg/kg/day of lisinopril/hydrochlorothiazide showed physical signs that were attributable to drug treatment; these included decreased activity, dehydration and anorexia. Marked increases in the serum concentrations of urea nitrogen (128.4 to 271.5 mg/100 mL), creatinine (5.1 to 11.5 mg/100 mL), and phosphorus (9.2 to >16.0 mg/100 mL) in terminal samples of 3 dogs given 10/10 mg/kg/day of lisinopril/hydrochlorothiazide that were sacrificed due to their poor physical condition after 11 or 18 doses. These dogs had renal tubular necrosis and secondary lymphoid depletion, and gastrointestinal lesions. At 3/10 mg/kg/day, an increase in serum urea nitrogen was seen. At all doses decreases in serum sodium, potassium, and chloride occurred probably due to hydrochlorothiazide.
Dog	27 week	3 M + 3 F	Oral	Lisinopril/Hydrochlorothiazide 0/0, 0.3/1, 1/3, 3/10 mg/kg/day	All dogs given 3/10 mg/kg/day had elevations in serum urea nitrogen and some had increases in serum creatinine. One dog at this level was markedly affected with increases in serum urea nitrogen, creatinine, glucose, GOT, and GPT and decreases in serum sodium, chloride, and potassium. This dog was killed in the fifth week and had renal tubular degeneration and secondary lymphoid depletion and gastro-intestinal lesions. A transient decrease in blood erythroid parameters were seen at the highest dosage level and a decrease in serum sodium and at necropsy males in this group had a mild hypertrophy of the renal proximal tubules probably due to hypokalemia. The only changes seen at 0.3/1 and 1/3 mg/kg/day were decreases in serum potassium and chloride, and elevation in serum urea nitrogen at 1/3 mg/kg/day.

Teratology (lisinopril and hydrochlorothiazide)

Species	Duration	No of Animals/Group	Route	Dose mg/kg/day	Effects
Mouse	4 week	25 F	Oral	Lisinopril/Hydrochlorothiazide 0/0, 10/10, 30/10, 90/10 mg/kg, 90/10 mg/kg + 0.9% Saline – Days 6 - 15 of gestation	There were no maternal deaths and no treatment-related abortions. In all drug-treated groups there were no treatment-related effects on mean live fetal weights and numbers of implants and live and dead fetuses. There was a dose-response increase in incidence of skeletal malformations. In addition, there was an increase in the incidence of lumbar ribs, a skeletal-variation, among drug-treated groups. All of the skeletal malformations, with the exception of the fetus with the extra vertabra, were among mice not given saline supplementation and have occurred at comparable incidences in control groups of other studies, and some were observed in the control group of this study. A repeat of this study did not produce any evidence of treatment-related fetal skeletal malformations.
Rat	4 week	25 F	Oral	Lisinopril/Hydrochlorothiazide 0/0, 10/10, 30/10, 90/10 mg/kg, 90/10 mg/kg + 0.9% Saline – Days 6 - 17 of gestation	In the lisinopril/hydrochlorothiazide 90/10 mg/kg/day group, there was a significant ($P \leq 0.05$) decrease in the number of live fetuses per pregnant female. Maternotoxicity was evident in all unsupplemented drug-treated groups. There were significant ($P \leq 0.05$) treatment-related decreases in live fetal weight in all drug-treated groups not supplemented with saline. Fetal weight in the 90/10 mg/kg/day group supplemented with saline was comparable to control. There was an increased incidence of fetuses with incompletely ossified sternebrae in the 30/10 and 90/10 mg/kg/day groups without saline supplementation which were considered to represent an embryotoxic effect. Ossification was not delayed in the 10/10 mg/kg/day group or the 90/10 mg/kg/day group supplemented with saline.
Rat	4 week	20 or 22 F	Oral	Lisinopril/Hydrochlorothiazide 0/0, 3/10, 30/10, 90/10 mg/kg + 0.9% Saline – Days 6 - 17 of gestation	Fetotoxicity was apparent as treatment-related decreases in live fetal weight at all dosage levels without saline supplementation which were statistically significant ($P \leq 0.05$) in the 30/10 and 90/10 mg/kg/day groups. Results from this study confirmed those of the previous study. There was a delay in ossification, consistent with decreased live fetal weights, at all dosage levels without saline supplementation. Maternotoxicity was evident in all unsupplemented drug-treated groups.

Mutagenicity (lisinopril and hydrochlorothiazide)

The results of a battery of mutogenic and chromosomal aberration studies (Ames test, mammalian cell mutagenesis assay, an *in vitro* alkaline elution test for single strand DNA breaks, an *in vitro* chromosomal aberration assay in Chinese hamster ovary cells, and *in vivo* mouse bone marrow chromosome aberration) failed to reveal a genotoxic potential for the combination of lisinopril and hydrochlorothiazide.

REFERENCES

1. Ajayi AA, Campbell BC, Howie CA, Reid JL. Acute and chronic effects of the converting enzyme inhibitors enalapril and lisinopril on reflex control of heart rate in normotensive man. J Hypertens 1985;3:47-53.

2. Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 1977;12:297-303.

3. Biollaz J, Schelling JL, Jacot des Combes B, Brunner DB, Desponds G, Brunner HR, Ulm EH, Hichens M, Gomez HJ. Enalapril maleate and a lysine analogue (MK-521) in normal volunteers: Relationship between plasma drug levels and the renin angiotensin system. Br J Clin Pharmacol 1982;14:363-368.

4. Bussien JP, Waeber B, Nussberger J, Gomez HJ, Brunner HR. Once-daily lisinopril in hypertensive patients: Effect on blood pressure and the renin-angiotensin system. Curr Therapeutic Research 1985;37:342-351.

5. Cirillo VJ, Gomez HJ, Salonen J, Salonen R, Rissanen V, Bolognese JA, Nyberg R, Kristianson K. Lisinopril: Dose-peak effect relationship in essential hypertension. Br J Clin Pharmacol 1988;25:533-538.

6. Donohoe JF, Kelly J, Laher MS, Doyle GD. Lisinopril in the treatment of hypertensive patients with renal impairment. Am J Med 1988;85(Suppl 3B):31-34.

7. Laher MS, Natin D, Rao SK, Jones RW, Carr P. Lisinopril in elderly patients with hypertension. J Cardiovasc Pharmacol 1987;9(Suppl 3):S69-S71.

8. Lancaster SG, Todd PA. Lisinopril: A preliminary review of its Pharmacokinetics Properties, and Therapeutic Use in Hypertension and Congestive Heart Failure. Drugs 1988;35:646-669.

9. Millar JA, Derkx FHM, McLean K, Reid JL. Pharmacodynamics of converting enzyme inhibition: The cardiovascular endocrine and autonomic effects of MK-421 (enalapril) and MK-521. Br J Clin Pharmacol 1982;14:347-355.

10. Rotmensch HH, Vlasses PH, Swanson BN, Irvin JD, Harris KE, Merrill DD, Ferguson RD. Antihypertensive efficacy of once daily MK-521, a new nonsulfhydryl angiotensin-converting enzyme inhibitor. Am J Cardiol 1984;53:116-119.

11. Ulm EH, Hichens M, Gomez HJ, Till AE, Hand E, Vassil TC, Biollaz J, Brunner HR, Schelling JL. Enalapril maleate and a lysine analogue (MK-521): Disposition in man. Br J Clin Pharmacol 1982;14:357-362.

12. Product Monograph for PRINZIDE® by Merck Frosst Canada Ltd., Quebec, Canada. Date of Preparation: May 30, 2005. Date of Revision: November 7, 2006.

13. A blinded, single dose, randomized, 3-way crossover study between Lisinopril/Hydrochlorothiazide 20 mg/12.5 mg Tablets (Sanis Health Inc., Canada) and Zestoretic® 20 mg/12.5 mg Tablets (AstraZeneca Canada Inc.) and Prinzide® 20 mg/12.5 mg Tablets (Merck Frosst Canada & Co.). Data on file at Sanis Health Inc.

14. A blinded, single dose, randomized, 3-way crossover study between Lisinopril/Hydrochlorothiazide 20 mg/25 mg Tablets (Sanis Health Inc., Canada) and Zestoretic® 20 mg/25 mg Tablets (AstraZeneca Canada Inc.) and Prinzide® 20 mg/25 mg Tablets (Merck Frosst Canada & Co.). Data on file at Sanis Health Inc.